Germany · Delayed Price · Currency is EUR Pulse Biosciences Company Description
Pulse Biosciences, Inc. operates as a novel bioelectric medicine company.
It offers CellFX System, a novel Nanosecond Pulsed-Field Ablation delivery platform to treat benign lesions of the skin; CellFX nsPFA Percutaneous Electrode system for soft tissue ablation in surgical setting; CellFX nsPFA Cardiac Clamp designed for use in surgical treatment of atrial fibrillation (AF); CellFX nsPFA 360° Cardiac Catheter designed to provide a circumferential, or circular, ablation in a single treatment cycle; and The CellFX Consol, a tunable, software-enabled, and console-based platform designed to accommodate the clinical workflow preferred by physicians.
The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015.
Pulse Biosciences, Inc. was incorporated in 2014 and is headquartered in Miami, Florida.
| Country | United States |
| Founded | 2014 |
| Industry | Electromedical and Electrotherapeutic Apparatus |
| Employees | 75 |
| CEO | Paul LaViolette |
Contact Details
Address: 601 Brickell Key Drive Miami, Delaware 33131 United States | |
| Phone | 510 906 4600 |
| Website | pulsebiosciences.com |
Stock Details
| Ticker Symbol | 6L8 |
| Exchange | Frankfurt Stock Exchange |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| SIC Code | 3845 |
Key Executives
| Name | Position |
|---|---|
| Paul LaViolette | Chief Executive Officer |
| Jon Skinner | Chief Financial Officer |
| Edison Manuel | Chief Operating Officer |